KALM-2: CR845 in Hemodialysis Patients with Pruritus

Phase 3, randomised, double-blind trial in uremic pruritus comparing CR845 0.5mcg/kg with Placebo (2 arms). Primary endpoint: Reduction of Itch Intensity as Assessed by the Percentage of Patients Achieving an Improvement From Baseline >=3 Points With Respect to the Weekly Mean of the Daily 24-hour Worst Itching Intensity… at 12 weeks. Started Jul 2018; status: completed.